Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Continuous Flow
100%
Platelet Activation
100%
Mechanical Circulatory Support
100%
Platelet Aggregation
69%
Continuous-flow Pump
45%
Von Willebrand Factor
41%
Thrombotic Events
38%
Sildenafil
31%
Ischemic Stroke
31%
ADAMTS13
20%
Pump Thrombosis
20%
Multimers
20%
Thrombotic
20%
Ultra-large
20%
Potentiation
20%
Prothrombotic State
20%
Hematologic
20%
Low Platelets
20%
Nitric Oxide Signaling
17%
Mean Platelet Volume
15%
Platelets
15%
In Situ Thrombosis
10%
Chronic Heart
10%
Device Operation
10%
Acute Cardiogenic Shock
10%
End-stage Heart Failure
10%
Thrombus Formation
10%
Impella
10%
Therapeutic Target
10%
Heart Failure
10%
Surrogate Marker
10%
Placebo
10%
Hemolytic Disease
10%
Serious Adverse Events
10%
In Situ
10%
Thrombus
10%
Nitric Oxide
10%
Extracellular Hemoglobin
10%
Device Design
10%
Blood Flow
10%
Device-related Thrombus
10%
Substantial Reduction
10%
Venoarterial Extracorporeal Membrane Oxygenation (VA-ECMO)
10%
Hemocompatability
10%
Factor Levels
10%
Severe Heart Failure
10%
Adverse Events
10%
Phosphodiesterase Type 5 Inhibitors
10%
Platelet Activity
10%
End-organ Damage
10%
Thrombosis
10%
Antithrombotic Strategies
10%
Mechanical Circulatory Support Devices
10%
Flow Passage
7%
Cyclic GMP
7%
Sickle Cell Anemia
7%
Downstream Effects
7%
Metalloproteinases
7%
Drug Administration
7%
Medicine and Dentistry
Assisted Circulation
100%
Thrombocyte Activation
100%
Hemolysis
100%
Thrombocyte Aggregation
49%
Thrombosis
36%
Von Willebrand Factor
29%
Sildenafil
22%
Congestive Heart Failure
21%
Apoplexy
20%
Brain Ischemia
19%
Platelet
18%
Nitric Oxide
18%
Von Willebrand Factor Cleaving Proteinase
14%
Adverse Event
14%
Mean Platelet Volume
9%
Protein Degradation
7%
Cardiogenic Shock
7%
Disease Marker
7%
Blood Flow
7%
Hemolytic
7%
Placebo
7%
Outpatient
7%
Blood Clotting
7%
Thrombus
7%
Hemoglobins
7%
Therapeutic Target
7%
Morbidity
7%
Antithrombotic
6%
End Organ Damage
6%
Phosphodiesterase V
6%
Oral
6%
Pharmacology, Toxicology and Pharmaceutical Science
Hemolysis
80%
Von Willebrand Factor
38%
Thrombosis
38%
Sildenafil
28%
Brain Ischemia
23%
Thrombus
19%
Von Willebrand Factor Cleaving Proteinase
19%
Congestive Heart Failure
19%
Nitric Oxide
14%
Disease Marker
9%
Cerebrovascular Accident
9%
Adverse Event
9%
Morbidity
9%
Cardiogenic Shock
9%
Hemoglobins
9%
Placebo
9%